beta

CSTL

Castle Biosciences Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq).Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.

Market Cap: 1.8 Billion

Primary Exchange: NASDAQ/NMS (GLOBAL MARKET)

Website: www.castlebiosciences.com

Shares Outstanding: 25.1 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.21525874981462

Sector: Professional, Scientific, and Technical Services

Industry: Research and Development in Biotechnology

Ethical Flags

Longest drawdown: 124 trading days

From: 2021-02-09 To: 2021-06-15

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud